Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.
Herbst RS, Garon EB, Kim DW, Cho BC, Gervais R, Perez-Gracia JL, Han JY, Majem M, Forster MD, Monnet I, Novello S, Gubens MA, Boyer M, Su WC, Samkari A, Jensen EH, Kobie J, Piperdi B, Baas P. Herbst RS, et al. Among authors: garon eb. J Thorac Oncol. 2021 Oct;16(10):1718-1732. doi: 10.1016/j.jtho.2021.05.001. Epub 2021 May 26. J Thorac Oncol. 2021. PMID: 34048946 Free article. Clinical Trial.
Intracellular signaling molecules.
Garon EB, Dubinett SM. Garon EB, et al. J Thorac Oncol. 2009 Nov;4(11 Suppl 3):S1057-8. doi: 10.1097/01.JTO.0000361748.94541.7a. J Thorac Oncol. 2009. PMID: 19861915 Free article. No abstract available.
Novel drugs--miscellaneous category.
Hosmer WD, Dubinett SM, Garon EB. Hosmer WD, et al. Among authors: garon eb. J Thorac Oncol. 2010 Dec;5(12 Suppl 6):S468-9. doi: 10.1097/01.JTO.0000391369.48635.23. J Thorac Oncol. 2010. PMID: 21102242 Free article. No abstract available.
Mitotic inhibitors.
Garon EB, Dubinett SM. Garon EB, et al. J Thorac Oncol. 2011 Nov;6(11 Suppl 4):S1791-2. doi: 10.1097/01.JTO.0000407560.61287.3f. J Thorac Oncol. 2011. PMID: 22005532 Free PMC article. No abstract available.
A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design.
Garon EB, Cao D, Alexandris E, John WJ, Yurasov S, Perol M. Garon EB, et al. Clin Lung Cancer. 2012 Nov;13(6):505-9. doi: 10.1016/j.cllc.2012.06.007. Epub 2012 Jul 31. Clin Lung Cancer. 2012. PMID: 22853980 Clinical Trial.
Targeting MEK for the treatment of non-small-cell lung cancer.
Goldman JW, Garon EB. Goldman JW, et al. Among authors: garon eb. J Thorac Oncol. 2012 Dec;7(16 Suppl 5):S377-8. doi: 10.1097/JTO.0b013e31826df0bc. J Thorac Oncol. 2012. PMID: 23160324 Free PMC article. Review. No abstract available.
Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer.
Choy H, Schwartzberg LS, Dakhil SR, Garon EB, Gerber DE, Choksi JK, Govindan R, Peng G, Koustenis A, Treat J, Obasaju C. Choy H, et al. Among authors: garon eb. J Thorac Oncol. 2013 Oct;8(10):1308-16. doi: 10.1097/JTO.0b013e3182a02546. J Thorac Oncol. 2013. PMID: 23981966 Free PMC article. Clinical Trial.
197 results